Maryland Resident Population Per Square Mile: 2010-2020

Resident population density for Maryland and Jurisdictions per square mile from 2010 to 2020. Source: U.S. Bureau of Census

Pennsylvania Professional Licensee Data County State

This dataset contains counts of professional licensees per each licensed occupation and is broken down by County of licensee. *Appearances of non-Pennsylvania counties in the data are due to practitioners that are either licensed to practice in Pennsylvania but live out of state or own a facility in Pennsylvania but live out of state. **Appearances of null values in the data are due to the county field being an optional field for a license application and the county does not auto populate based on the address at this point in time.

Dispensation Data without Buprenorphine Quarter 3 2016 - Current Quarterly County Health

View quarterly trends in opioid dispensation data for all Schedule II-V opioids. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx More information from U.S. Department of Justice https://www.deadiversion.usdoj.gov/schedules/ Schedule I Controlled Substances Substances in this schedule have no currently accepted medical use in the United States, a lack of accepted safety for use under medical supervision, and a high potential for abuse. Some examples of substances listed in Schedule I are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), peyote, methaqualone, and 3,4-methylenedioxymethamphetamine ("Ecstasy"). Schedule II/IIN Controlled Substances (2/2N) Substances in this schedule have a high potential for abuse which may lead to severe psychological or physical dependence. Examples of Schedule II narcotics include: hydromorphone (Dilaudid®), methadone (Dolophine®), meperidine (Demerol®), oxycodone (OxyContin®, Percocet®), and fentanyl (Sublimaze®, Duragesic®). Other Schedule II narcotics include: morphine, opium, codeine, and hydrocodone. Examples of Schedule IIN stimulants include: amphetamine (Dexedrine®, Adderall®), methamphetamine (Desoxyn®), and methylphenidate (Ritalin®). Other Schedule II substances include: amobarbital, glutethimide, and pentobarbital. Schedule III/IIIN Controlled Substances (3/3N) Substances in this schedule have a potential for abuse less than substances in Schedules I or II and abuse may lead to moderate or low physical dependence or high psychological dependence. Examples of Schedule III narcotics include: products containing not more than 90 milligrams of codeine per dosage unit (Tylenol with Codeine®), and buprenorphine (Suboxone®). Examples of Schedule IIIN non-narcotics include: benzphetamine (Didrex®), phendimetrazine, ketamine, and anabolic steroids such as Depo®-Testosterone. Schedule IV Controlled Substances Substances in this schedule have a low potential for abuse relative to substances in Schedule III. Examples of Schedule IV substances include: alprazolam (Xanax®), carisoprodol (Soma®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), lorazepam (Ativan®), midazolam (Versed®), temazepam (Restoril®), and triazolam (Halcion®). Schedule V Controlled Substances Substances in this schedule have a low potential for abuse relative to substances listed in Schedule IV and consist primarily of preparations containing limited quantities of certain narcotics. Examples of Schedule V substances include: cough preparations containing not more than 200 milligrams of codeine per 100 milliliters or per 100 grams (Robitussin AC®, Phenergan with Codeine®), and ezogabine.

Buprenorphine Dispensation Data Quarter 3 2016 - Current Quarterly Statewide Health

View quarterly trends in buprenorphine dispensation data. Please note that buprenorphine data received by the PDMP is restricted to prescriptions filled by pharmacies. The PDMP does not collect information on the reason a controlled substance is prescribed, nor does it collect data from substance abuse treatment facilities or dispensing prescribers providing buprenorphine for substance abuse treatment. Buprenorphine is sometimes prescribed off-label for pain. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

MD COVID-19 - Cases per 100K population, by jurisdiction

<b>Note:</b> Starting April 27, 2023 updates change from daily to weekly. <b>Summary</b> The rate of confirmed COVID-19 cases among Marylanders per 100,000 people in each Maryland jurisdiction. <b>Description</b> The MD COVID-19 cases per 100K population, by jurisdiction layer is the rate of confirmed daily COVID-19 cases among Marylanders per 100,000 people in each Maryland jurisdiction. This rate is a 7-day average, calculated using the CasesByCounty layer and the 2019 estimated county populations (Maryland Department of Planning). Any negative value may be attributed to changes in reporting by jurisdiction. <b>Terms of Use</b> The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.

Risky Prescribing Measures Quarter 3 2016 - Current Quarterly County & Statewide Health

View quarterly trends in Risky Prescribing Measures, including: o Number/Rate of Individuals Seeing 5+ Prescribers and 5+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 4+ Prescribers and 4+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals Seeing 3+ Prescribers and 3+ Dispensers: Number of individuals who received prescriptions from 5 or more prescribers AND 5 or more dispensers for any Schedule II-V substance in a 3-month period. This measure is also referred to as Multiple Provider Episodes. County rates are calculated based on the patient’s county of residence. o Number/Rate of Individuals with an Average Daily MME >50, >90 or >120: Average Daily MME is calculated as the sum of the total MME on each day in a time period based on all prescriptions an individual has filled divided by the number of days in the prescription(s). Measures include the number and rate of individuals prescribed greater than 50 MME per day, greater than 90 MME per day, or greater than 120 MME per day and is based on the patient’s county of residence. o Number/Rate of Individuals with Overlapping Opioid/Benzodiazepine Prescriptions: Number of individuals receiving overlapping opioid and benzodiazepine prescriptions during a given quarter. This measure is based on the patients’ county of residence. o Number/Rate of Individuals with > 30 Days of Overlapping Opioid/Benzodiazepine Prescriptions: Number and rate of individuals receiving overlapping opioid and benzodiazepine prescriptions for 30 days or more during a given quarter using state/county populations as denominators. This measure is based on the patients’ county of residence. Please see PDMP Data Technical Notes for additional details: https://www.health.pa.gov/topics/programs/PDMP/Pages/Data.aspx

Individuals under Medical Assistance (Newly Eligible) Diagnosed with Opioid Use Disorder CY 2015-Current Annual County Human Services

This dataset contains the total counts of PA Department of Human Services (DHS) Medical Assistance (MA) individuals diagnosed with Opioid Use Disorder (OUD) or OUD Poisoning. Also included are individuals receiving MAT (Medication assisted treatment - the use of medications in combination with counseling and behavioral therapies for the treatment of substance use disorders.) NOT diagnosed in the same period. Limited to the Newly Eligible (Under the Medical Assistance Expansion Program. Find more information here: http://www.dhs.pa.gov/cs/groups/webcontent/documents/document/c_257436.pdf) segment of DHS population. Internally defined as DHS Category of Assistance = MG (Modified Adjusted Gross Income - MAGI) MG and Program Status = 91 (Newly Eligible). Counts are reported by Pennsylvania case county and covers calendar years 2015 -2018.

MD COVID-19 - Total Population Tested by County

<b>Summary</b> This layer is deprecated (Last updated 3/14/2022). The total number of residents who have been administered at least one COVID-19 test in each Maryland jurisdiction. <b>Description</b> Data represent the number of Maryland residents, both in number and by percent of the population, who have been tested for COVID-19 at least once each Maryland jurisdiction. <b>Terms of Use</b> The Spatial Data, and the information therein, (collectively the "Data") is provided "as is" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.

MUNICIPAL_BOUNDARY

MTA Transit Oriented Development (TOD) Data

*** DISCLAIMER - This web page is a public resource of general information. The Maryland Mass Transit Administration (MTA) makes no warranty, representation, or guarantee as to the content, sequence, accuracy, timeliness, or completeness of any of the spatial data or database information provided herein. MTA and partner state, local, and other agencies shall assume no liability for errors, omissions, or inaccuracies in the information provided regardless of how caused; or any decision made or action taken or not taken by any person relying on any information or data furnished within. *** This dataset assesses rail station potential for different forms of transit oriented development (TOD). A key driver of increased transit ridership in Maryland, TOD capitalizes on existing rapid transit infrastructure. The online tool focuses on the MTA’s existing MARC Commuter Rail, Metro Subway, and Central Light Rail lines and includes information specific to each station. The goal of this dataset is to give MTA planning staff, developers, local governments, and transit riders a picture of how each MTA rail station could attract TOD investment. In order to make this assessment, MTA staff gathered data on characteristics that are likely to influence TOD potential. The station-specific data is organized into 6 different categories referring to transit activity; station facilities; parking provision and utilization; bicycle and pedestrian access; and local zoning and land availability around each station. As a publicly shared resource, this dataset can be used by local communities to identify and prioritize area improvements in coordination with the MTA that can help attract investment around rail stations. You can view an interactive version of this dataset at geodata.md.gov/tod. ** Ridership is calculated the following ways: Metro Rail ridership is based on Metro gate exit counts. Light Rail ridership is estimated using a statistical sampling process in line with FTA established guidelines, and approved by the FTA. MARC ridership is calculated using two (2) independent methods: Monthly Line level ridership is estimated using a statistical sampling process in line with FTA established guidelines, and approved by the FTA. This method of ridership calculation is used by the MTA for official reporting purposes to State level and Federal level reporting. Station level ridership is estimated by using person counts completed by the third party vendor. This method of calculation has not been verified by the FTA for statistical reporting and is used for scheduling purposes only. However, because of the granularity of detail, this information is useful for TOD applications. *Please note that the monthly level ridership and the station level ridership are calculated using two (2) independent methods that are not interchangeable and should not be compared for analysis purposes.